explore -WSS

explore

author：focus 2025-09-30 00:35:39 - browse：93568

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Cancer drug shortages should be causing more outrage
Next article： Mega Millions pot grows to $1.25 billion after no winner

Wikipedia

WSS

The woman behind the Dana Farber

NIH launches clinical trials and new research office for long Covid

Canadian Prime Minister Justin Trudeau separating from wife, Sophie

Mega Millions pot grows to $1.25 billion after no winner

Wildfire pollution widens asthma inequities on Long Island

Trump indictment: Who are the 'co

entertainment

explore

entertainment

Medical leaders decry Supreme Court decision on affirmative action

FDA approves world's first CRISPR

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA approves world's first CRISPR

ChatGPT in medicine: STAT answers readers' burning questions

EQRx, failed developer of low

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Mitch McConnell episode has important public health takeaway

In Memoriam: Notable people who died in 2023

SCOTUS to consider access to abortion pill mifepristone

focus

The high personal cost of affirmative action for Black doctors

Physician groups backed by private equity giant lobby on mergers

The high personal cost of affirmative action for Black doctors

Mitch McConnell episode has important public health takeaway

EQRx, failed developer of low

What to expect as Trump is arraigned on his Jan 6. indictment

knowledge

Wikipedia

explore

focus